Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 325 versus CONRAY 43.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 325 versus CONRAY 43.
CONRAY 325 vs CONRAY 43
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays by blocking photons, allowing visualization of blood vessels and tissues.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Intravenous: 1.0-2.0 mL/kg (325 mg I/mL) for contrast imaging; maximum total dose 250 mL.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours in patients with normal renal function. May be prolonged in renal impairment.
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (glomerular filtration); >95% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent